{"id":"lansoprazole","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"7.4%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Alcoholism","Anemia","Blood coagulation disorder","Body fluid retention","Cardiovascular event risk","Cerebrovascular accident","Cholestatic hepatitis","Chronic heart failure","Coronary artery bypass graft","Disease of liver","Disorder of cardiovascular system","Edema","Esophageal dysmotility","Fracture of bone","Gastrointestinal hemorrhage","Gastrointestinal ulcer","Hepatic failure","Hypertensive disorder","Hypomagnesemia","Infectious mononucleosis","Kidney disease","Liver function tests abnormal","Myasthenia gravis","Myocardial infarction","Obstruction of bile duct","Osteoporosis","Porphyria","Pregnancy, function","Prolonged QT interval","Pseudomembranous enterocolitis","Smokes tobacco daily","Thromboembolic disorder","Torsades de pointes","Ventricular tachycardia"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Cerebrovascular accident/cerebral infarction","drugRate":"","severity":"serious"},{"effect":"Gastrointestinal hemorrhage","drugRate":"","severity":"serious"},{"effect":"Hematemesis","drugRate":"","severity":"serious"},{"effect":"Melena","drugRate":"","severity":"serious"},{"effect":"Esophageal ulcer","drugRate":"","severity":"serious"},{"effect":"Esophageal stenosis","drugRate":"","severity":"serious"},{"effect":"Shock (circulatory failure)","drugRate":"","severity":"serious"},{"effect":"Syncope","drugRate":"","severity":"serious"},{"effect":"Carcinoma","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT05448001","NCT04877834","NCT03801148","NCT02150447","NCT02175901","NCT06945237","NCT05624229","NCT00255164","NCT01906879","NCT03488173","NCT00220818","NCT04022096","NCT03716622","NCT02541786","NCT00239551","NCT00523367","NCT01418300","NCT00251745","NCT02099708","NCT05267743","NCT02625259","NCT02530879","NCT00787254","NCT07479056","NCT05259007","NCT01452724","NCT00204373","NCT00847808","NCT03079050","NCT02162758","NCT07337655","NCT00701259","NCT00952913","NCT03011125","NCT02555852","NCT03675672","NCT02761512","NCT04729101","NCT03654781","NCT03488186","NCT00442013","NCT04311541","NCT03124420","NCT01922505","NCT05010954","NCT07487142","NCT02794844","NCT02037399","NCT02646332","NCT03202537"],"aliases":["Prevacid","Zoton"],"patents":[{"type":"Formulation","number":"11077055","applicant":"DEXCEL PHARMA TECHNOLOGIES LTD","territory":"US","tradeName":"LANSOPRAZOLE","expiryDate":"2036-04-21"},{"type":"Formulation","number":"11986554","applicant":"DEXCEL PHARMA TECHNOLOGIES LTD","territory":"US","tradeName":"LANSOPRAZOLE","expiryDate":"2036-04-21"}],"pricing":[],"allNames":"prevacid","offLabel":[],"timeline":[],"aiSummary":"Lansoprazole (Prevacid) is a proton pump inhibitor approved in 1995, developed by Takeda. Now available OTC and generically, it provides effective acid suppression with rapid onset of action.","brandName":"Prevacid","companyId":"unknown","ecosystem":[],"mechanism":{"target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","novelty":"","modality":"Small molecule","drugClass":"Proton pump inhibitor (PPI)","explanation":"Lansoprazole is a PPI with rapid onset of action, typically providing symptom relief within 1-3 days. Available in an orally disintegrating tablet formulation useful for patients with swallowing difficulties.","oneSentence":"Irreversibly inhibits the gastric proton pump to suppress acid secretion.","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Generic (originally Takeda)","competitors":[],"genericName":"lansoprazole","indications":{"approved":[{"name":"Duodenal Ulcer due to H. Pylori","diseaseId":"duodenal-ulcer-due-to-h.-pylori","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Duodenal ulcer disease","diseaseId":"duodenal-ulcer-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erosive esophagitis","diseaseId":"erosive-esophagitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gastric Hypersecretory Conditions","diseaseId":"gastric-hypersecretory-conditions","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gastric ulcer","diseaseId":"gastric-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gastroesophageal reflux disease","diseaseId":"gastroesophageal-reflux-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Maintenance of Healing Duodenal Ulcer","diseaseId":"maintenance-of-healing-duodenal-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"NSAID-Induced Gastric Ulcer","diseaseId":"nsaid-induced-gastric-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Peptic ulcer","diseaseId":"peptic-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Zollinger-Ellison syndrome","diseaseId":"zollinger-ellison-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05448001","phase":"Phase 3","title":"A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer","status":"COMPLETED","sponsor":"Onconic Therapeutics Inc.","isPivotal":true,"enrollment":329,"indication":"Gastric Ulcer","completionDate":"2024-07-19"},{"nctId":"NCT04877834","phase":"Phase 1","title":"A Single Center, Open Label, Randomized, Single-dose, Two-period, Two-way Cross-over Study to Compare the Rate and Extent of Absorption of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60m","status":"COMPLETED","sponsor":"University of Karachi","isPivotal":false,"enrollment":60,"indication":"Healthy, Bioequivalence Study","completionDate":"2022-11-25"},{"nctId":"NCT03801148","phase":"Phase 1","title":"A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period, Two-Part Crossover Study in Healthy Subjects to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed-R","status":"COMPLETED","sponsor":"Takeda","isPivotal":false,"enrollment":122,"indication":"Healthy Volunteers","completionDate":"2019-04-09"},{"nctId":"NCT02150447","phase":"Phase 3","title":"Effect of Proton Pump Inhibitor on Prevention of Tumor Bleeding in Patients Under Palliative Chemotherapy for Unresectable Gastric Cancer: a Randomized, Double Blind, and Placebo Controlled Multicente","status":"TERMINATED","sponsor":"National Cancer Center, Korea","isPivotal":true,"enrollment":394,"indication":"Gastric Cancer, Bleeding","completionDate":"2017-05"},{"nctId":"NCT02175901","phase":"Phase 4","title":"Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line H","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","isPivotal":false,"enrollment":215,"indication":"Dyspepsia, Peptic Ulcer","completionDate":"2015-01"},{"nctId":"NCT06945237","phase":"NA","title":"A Randomized Controlled Study on the Efficacy and Safety of Gut-Brain Neuromodulators in Patients With Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"RenJi Hospital","isPivotal":false,"enrollment":164,"indication":"Gastroesophageal Reflux Disease","completionDate":"2025-10-30"},{"nctId":"NCT05624229","phase":"Phase 4","title":"Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","isPivotal":false,"enrollment":672,"indication":"Upper Gastrointestinal Hemorrhage","completionDate":"2028-12-31"},{"nctId":"NCT00255164","phase":"Phase 3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","isPivotal":true,"enrollment":451,"indication":"Esophagitis, Reflux, Esophagitis, Peptic","completionDate":"2006-11"},{"nctId":"NCT01906879","phase":"Phase 4","title":"Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":1620,"indication":"Helicobacter Pylori Infection","completionDate":"2017-12"},{"nctId":"NCT03488173","phase":"Phase 1","title":"Pharmacokinetic Study of Lansoprazole Capsules in Healthy Chinese Volunteer","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","isPivotal":false,"enrollment":42,"indication":"Effect of Drugs, Safety Issues","completionDate":"2019-04-24"},{"nctId":"NCT00220818","phase":"Phase 1","title":"A Phase 1, Single- and Repeated-Dose, Randomized, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Lansoprazole in Infants With Clinically-Evident Gastroe","status":"COMPLETED","sponsor":"Takeda","isPivotal":false,"enrollment":24,"indication":"Gastroesophageal Reflux Disease","completionDate":"2005-07"},{"nctId":"NCT04022096","phase":"Phase 3","title":"A Phase 3, Double-blind, Randomized, Active-controlled Study to Evaluate the Safety and Efficacy of Tegoprazan as Maintenance Therapy in Patients With Healed Erosive Esophagitis","status":"COMPLETED","sponsor":"HK inno.N Corporation","isPivotal":true,"enrollment":351,"indication":"Healed Erosive Esophagitis","completionDate":"2021-06-23"},{"nctId":"NCT03716622","phase":"Phase 4","title":"A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","isPivotal":false,"enrollment":350,"indication":"Helicobacter Pylori","completionDate":"2019-08-31"},{"nctId":"NCT02541786","phase":"Phase 4","title":"Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Medical University","isPivotal":false,"enrollment":177,"indication":"Helicobacter Pylori Infection","completionDate":"2015-08"},{"nctId":"NCT00239551","phase":"Phase 4","title":"Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer","status":"COMPLETED","sponsor":"Emory University","isPivotal":false,"enrollment":30,"indication":"Stomach Ulcer","completionDate":"2007-12"},{"nctId":"NCT00523367","phase":"NA","title":"COPD Patients Diagnosed With Gastro Esophageal Reflux Disease Have Decreased Rates of COPD Exacerbations After Treatment With High Dose Proton Pump Inhibitor Therapy (Esomeprazole or Lansoprazole)","status":"TERMINATED","sponsor":"University of Florida","isPivotal":false,"enrollment":25,"indication":"Gastroesophageal Reflux, Chronic Obstructive Pulmonary Disease","completionDate":"2010-10"},{"nctId":"NCT01418300","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Jun-Won Chung","isPivotal":false,"enrollment":159,"indication":"Helicobacter Infected Patients","completionDate":"2011-12"},{"nctId":"NCT00251745","phase":"Phase 3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesop","status":"COMPLETED","sponsor":"Takeda","isPivotal":true,"enrollment":908,"indication":"Gastroesophageal Reflux Disease","completionDate":"2006-05"},{"nctId":"NCT02099708","phase":"N/A","title":"Takepron Capsules 15/ Orally Dispersing（OD） Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal ","status":"COMPLETED","sponsor":"Takeda","isPivotal":false,"enrollment":3502,"indication":"Gastric or Duodenal Ulcers","completionDate":"2014-03"},{"nctId":"NCT05267743","phase":"Phase 4","title":"A Multicenter, Double-blind, Randomized, Active-controlled Phase 4 Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients With Erosive Reflux Disease","status":"COMPLETED","sponsor":"HK inno.N Corporation","isPivotal":false,"enrollment":218,"indication":"Erosive Reflux Disease","completionDate":"2022-05-25"},{"nctId":"NCT02625259","phase":"Phase 1","title":"A Phase 1, Open-Label Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric pH Modification on the Pharmacokinetics of MLN1117 in Healthy Subjects","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","isPivotal":false,"enrollment":54,"indication":"Neoplasm, Advanced or Metastatic","completionDate":"2016-07-22"},{"nctId":"NCT02530879","phase":"Phase 4","title":"Comparison of Voice Therapy and Antireflex Therapy in the Treatment of Laryngopharyngeal Reflux-related Hoarseness: A Prospective Randomized Control Trial","status":"WITHDRAWN","sponsor":"Temple University","isPivotal":false,"enrollment":0,"indication":"Laryngopharyngeal Reflux","completionDate":"2018-01"},{"nctId":"NCT00787254","phase":"Phase 3","title":"A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug","status":"COMPLETED","sponsor":"Takeda","isPivotal":true,"enrollment":366,"indication":"Stomach Ulcer, Duodenal Ulcer","completionDate":"2009-05"},{"nctId":"NCT07479056","phase":"NA","title":"Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary","status":"RECRUITING","sponsor":"SUK MIN SEO","isPivotal":false,"enrollment":400,"indication":"Diseases of the Circulatory System, Angina Pectoris, Unspecified","completionDate":"2028-12-31"},{"nctId":"NCT05259007","phase":"Phase 4","title":"The Effect of Propolis and Nutritional Education in Patients With H. Pylori on Gastrointestinal Symptoms","status":"UNKNOWN","sponsor":"Fatma Zehra Arvas","isPivotal":false,"enrollment":96,"indication":"Helicobacter Pylori Infection","completionDate":"2022-04-05"},{"nctId":"NCT01452724","phase":"Phase 3","title":"A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in P","status":"COMPLETED","sponsor":"Takeda","isPivotal":true,"enrollment":372,"indication":"Duodenal Ulcer","completionDate":"2013-02"},{"nctId":"NCT00204373","phase":"Phase 4","title":"Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors","status":"COMPLETED","sponsor":"Charles Mel Wilcox, MD","isPivotal":false,"enrollment":72,"indication":"Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia","completionDate":"2010-12"},{"nctId":"NCT00847808","phase":"Phase 3","title":"A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Prot","status":"COMPLETED","sponsor":"Takeda","isPivotal":true,"enrollment":178,"indication":"Gastroesophageal Reflux","completionDate":"2010-04"},{"nctId":"NCT03079050","phase":"Phase 4","title":"An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","isPivotal":false,"enrollment":33,"indication":"GERD, Proton Pump Inhibitor","completionDate":"2017-07-30"},{"nctId":"NCT02162758","phase":"Phase 2","title":"A Randomized, Double-Blind, Phase 4 Study to Evaluate the Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of ","status":"TERMINATED","sponsor":"Takeda","isPivotal":false,"enrollment":6,"indication":"Barrett's Esophagus","completionDate":"2016-04"},{"nctId":"NCT07337655","phase":"Phase 2","title":"A Phase II/III Clinical Trial Evaluating the Efficacy and Safety of Aspirin and Lansoprazole in High-Risk Pregnant Women for the Prevention of Preterm Birth: A Biomarker-Enriched Design","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","isPivotal":true,"enrollment":670,"indication":"Pre-term Birth","completionDate":"2032-09-30"},{"nctId":"NCT00701259","phase":"Phase 3","title":"A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of Fourteen Day Treatment With Lansoprazole 15 mg or 30 mg Once a Day in Frequent Nighttime Heartburn","status":"COMPLETED","sponsor":"Novartis","isPivotal":true,"enrollment":852,"indication":"Frequent Heartburn","completionDate":"2007-08"},{"nctId":"NCT00952913","phase":"Phase 1","title":"A Study to Examine The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib When Administered Concomitantly To Healthy Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":24,"indication":"Healthy","completionDate":"2009-10"},{"nctId":"NCT03011125","phase":"Phase 1","title":"A Phase 1 Double-blind, Dose-escalation, Placebo-controlled Tolerance Study in Healthy Chinese Adults After Single Intravenous Administration of Dexlansoprazole","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","isPivotal":false,"enrollment":28,"indication":"Safety Issues","completionDate":"2017-03-09"},{"nctId":"NCT02555852","phase":"N/A","title":"Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","isPivotal":false,"enrollment":4238504,"indication":"Gastroesophageal Reflux Disease (GERD), Community-acquired Pneumonia","completionDate":"2012-02"},{"nctId":"NCT03675672","phase":"Phase 4","title":"Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer: a Double-blind Randomised Trial on Misoprostol Combined With Lansoprazole Versus Lansoprazole Alone (NRT_MISO S","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","isPivotal":false,"enrollment":154,"indication":"Active Peptic Ulcer Disease/GI Bleeding","completionDate":"2027-03-31"},{"nctId":"NCT02761512","phase":"Phase 3","title":"A Double Blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer","status":"COMPLETED","sponsor":"HK inno.N Corporation","isPivotal":true,"enrollment":306,"indication":"Gastric Ulcer","completionDate":"2018-12-28"},{"nctId":"NCT04729101","phase":"Phase 1","title":"A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan (20 mg) and Lansoprazole (30 mg) in Healthy Subjects","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","isPivotal":false,"enrollment":44,"indication":"Healthy Participants","completionDate":"2021-06-26"},{"nctId":"NCT03654781","phase":"Phase 1","title":"Periodontal Tedavinin Helikobakter Pilori Eradikasyon ve Rekürrensine Katkısının İncelenmesi","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","isPivotal":false,"enrollment":98,"indication":"Helicobacter Pylori Infection","completionDate":"2012-02-17"},{"nctId":"NCT03488186","phase":"Phase 1","title":"A Randomized, Open Label, Parallel, Single and Multiple Doses Designed Clinical Study to Evaluate Comparative Pharmacokinetics (PK)-Pharmacodynamics (PD) After Oral Administration of Lansoprazole Caps","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","isPivotal":false,"enrollment":24,"indication":"Effect of Drugs, Safety Issues","completionDate":"2019-04-24"},{"nctId":"NCT00442013","phase":"Phase 4","title":"Phase III: The Study of Acid Reflux in Children With Asthma","status":"COMPLETED","sponsor":"Johns Hopkins University","isPivotal":false,"enrollment":306,"indication":"Asthma","completionDate":"2011-08"},{"nctId":"NCT04311541","phase":"N/A","title":"National, Multicentre, Observational, Non-Interventional Prospective Study of Dexlansoprazole MR in GERD Patients in the Russian Federation","status":"WITHDRAWN","sponsor":"Takeda","isPivotal":false,"enrollment":0,"indication":"Gastroesophageal Reflux Disease","completionDate":"2022-01-31"},{"nctId":"NCT03124420","phase":"Phase 4","title":"Intraluminal Therapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","isPivotal":false,"enrollment":100,"indication":"Helicobacter Pylori Infection","completionDate":"2018-04-30"},{"nctId":"NCT01922505","phase":"N/A","title":"The Trend of Eradication Rates of First-line Triple Therapy for Helicobacter Pylori and Clinical Factors That Affect the Eradication in Korean: Single Center Experience for Recent Ten Years","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","isPivotal":false,"enrollment":2500,"indication":"Helicobacter Infections","completionDate":"2013-05"},{"nctId":"NCT05010954","phase":"Phase 3","title":"A Multi-center, Randomized, Double-blind, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 Compared to Lansoprazole in the Treatment of Duodenal Ulcer in Chi","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","isPivotal":true,"enrollment":400,"indication":"Duodenal Ulcer","completionDate":"2022-09-28"},{"nctId":"NCT07487142","phase":"Phase 3","title":"\"Prevalence of Asymptomatic Helicobacter Pylori Infection Among Patients Undergoing Percutaneous Coronary Intervention and Impact of Its Eradication on Occurrence of Gastrointestinal Symptoms and Blee","status":"COMPLETED","sponsor":"Beni-Suef University","isPivotal":true,"enrollment":121,"indication":"H Pylori Infection","completionDate":"2025-12-24"},{"nctId":"NCT02794844","phase":"Phase 4","title":"Implementation of Pharmacogenomic Testing in Nemours Children's Health System","status":"COMPLETED","sponsor":"Nemours Children's Clinic","isPivotal":false,"enrollment":28,"indication":"Gastroesophageal Reflux","completionDate":"2018-08-31"},{"nctId":"NCT02037399","phase":"NA","title":"","status":"UNKNOWN","sponsor":"Yonsei University","isPivotal":false,"enrollment":50,"indication":"Early Gastric Cancer or Gastric Adenoma","completionDate":"2014-02"},{"nctId":"NCT02646332","phase":"NA","title":"Comparing the Efficacy and Impact on Gastrointestinal Microbiota of Reverse Hybrid Therapy and Concomitant Therapy in Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","isPivotal":false,"enrollment":248,"indication":"Helicobacter Pylori Infection","completionDate":"2020-08-31"},{"nctId":"NCT03202537","phase":"EARLY/Phase 1","title":"Effectiveness of Physiologic Testing in PPI Non-Responders","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":240,"indication":"Gastro Esophageal Reflux","completionDate":"2022-07-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Once daily","formulation":"Delayed-release capsule, Orally disintegrating tablet"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Pain"],"biosimilarFilings":[],"firstApprovalDate":"1995-05-10","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"11077055","territory":"US","patent_type":"Formulation","expiry_date":"2036-04-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11986554","territory":"US","patent_type":"Formulation","expiry_date":"2036-04-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}